0001209191-23-011777.txt : 20230222
0001209191-23-011777.hdr.sgml : 20230222
20230222173546
ACCESSION NUMBER: 0001209191-23-011777
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230218
FILED AS OF DATE: 20230222
DATE AS OF CHANGE: 20230222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KASINGER JAMES R.
CENTRAL INDEX KEY: 0001708172
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 23654787
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS, INC.
STREET 2: 610 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-18
0
0001674416
CRISPR Therapeutics AG
CRSP
0001708172
KASINGER JAMES R.
C/O CRISPR THERAPEUTICS, INC.
105 W FIRST STREET
BOSTON
MA
02127
0
1
0
0
General Counsel and Secretary
Common Shares
2023-02-18
4
M
0
3825
A
54016
D
Common Shares
2023-02-21
4
F
0
1950
48.26
D
52066
D
Restricted Stock Units
2023-02-18
4
M
0
3825
D
Common Shares
3825
11475
D
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
2023-02-22